CancerNCT05376891
Met Non Small Cell Cancer Registry (MOMENT)
An observational study of Cancer, run by EMD Serono Research & Development Institute, Inc. at 80 sites in 14 countries.
Trial summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cancer
- How many people
- 700 participants
- Where
- 80 sitesin 14 countries
- Study dates
- 4 Oct 2022to 28 Apr 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Participants with advanced stage (stages IIIB-IV) NSCLC and confirmed METex14 skipping alterations who are initiating or already treated with a systemic therapy will be included.
Who may be able to join
- Participants who signed ICF
- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
- Participants who are starting or are already being treated with systemic therapy
Who cannot join
- Participants who are enrolled in a clinical trial
Trial locations and contacts
80 sites in 14 countries. Contact the study team or a site near you to ask about taking part.
80 sites in 14 countries
United Kingdom15 sites, 14 recruiting
- Recruiting
Bedford General Hospital
Bedford
ramesh.bulusu@nhs.net
Venkata Bulusu
- Terminated
Birmingham Heartlands Hospital
Birmingham
- Recruiting
Royal Bournemouth Hospital
Bournemouth
tom.geldart@rbch.nhs.uk
Tom Geldart
- Recruiting
Velindre Cancer Centre
Cardiff, CF14 2TL
najmus.iqbal@wales.nhs.uk
Najmus Iqbal
- Recruiting
The Royal Marsden Hospital
Chelsea
sanjay.popat@rmh.nhs.uk
Sanjay Popat
- Recruiting
Northwick Park Hospital
Harrow
arshi.denton@nhs.net
Arshi Denton
- Not yet recruiting
Huddersfield Royal Infirmary
Huddersfield, West Yorkshire, HD3 3EA
milly.finch@cht.nhs.uk
Milly Finch
- Recruiting
Clatterbridge Cancer Centre - Liverpool
Liverpool
carles.escriu@nhs.net
Carles Escriu
- Not yet recruiting
Guy's Cancer Centre
London, SE1 9RT
daniel.hughes4@nhs.net
Daniel Hughes
- Recruiting
Queen Elizabeth Hospital,Woolwich
London, SE18 4QH
daniel.hughes4@nhs.net
Daniel Huges
- Recruiting
St. George's Hospital
London, SW17 0QT
Doraid.Alrifai@stgeorges.nhs.uk
Doriad Alrifai
- Recruiting
Charing Cross Hospital
London
joanne.evans10@nhs.net
Joanne Evans
- Recruiting
Preston Hospital
Preston
p.bezecny@nhs.net
Pavel Bezecny
- Recruiting
Great Western Hospital
Swindon, SN3 6BB
okhan@nhs.net
Omar Khan
- Recruiting
Torbay Hospital
Torquay, Devon, TQ2 7AA
louise.medley@nhs.net
Louise Medley
France9 sites, 9 recruiting
- Recruiting
Centre Hospitalier de Cholet
Cholet
philippe.masson@ch-cholet.fr
Philippe Masson
- Recruiting
CHRU Lille
Lille
alexis.cortot@chru-lille.fr
Alexis Benjamin Cortot
- Recruiting
Hôpital du Scorff
Lorient
r.lamy@ghbs.bzh
Régine Lamy
- Recruiting
Centre Leon Berard
Lyon
maurice.perol@lyon.unicancer.fr
Maurice Perol
- Recruiting
Groupe Hospitalier Paris Saint Joseph
Paris, 75014
chelissey@ghpsj.fr
Carole Helissey
- Recruiting
Hospital Tenon & University Paris 6
Paris
vincent.fallet@aphp.fr
Vincent Fallet
- Recruiting
Institut Curie - Centre de Lutte Contre le Cancer (CLCC)
Paris
nicolas.girard2@curie.fr
Nicolas Girard
- Recruiting
CHU de Pontchaillou
Rennes, 35 033
herve.lena@chu-rennes.fr
Hervé Lena
- Recruiting
CHU de Toulouse Hopital Larrey
Toulouse
mazieres.j@chu-toulouse.fr
Julien Mazieres
Italy9 sites, 9 recruiting
- Recruiting
Istituto Europeo di Oncologia
Milan
gianluca.spitaleri@ieo.it
Gianluca Spitaleri
- Recruiting
Istituto Nazionale Dei Tumori
Milan
giuseppe.lorusso@istitutotumori.mi.it
Giuseppe Lo Russo
- Recruiting
Humanitas Istituto Clinico Catanese
Misterbianco, Sicily, 95045
alessandro.russo@humanitascatania.it
Alessandro Russo
- Recruiting
Azienda Ospedaliero Universitaria di Modena
Modena, 41125
bertolini.federica@policlinico.mo.it
Federica Bertolini
- Recruiting
Azienda Ospedaliera Dei Colli - Ospedale Monaldi
Naples, 80131
giuseppe.viscardi@hotmail.it
Giuseppe Viscardi
- Recruiting
AOU dell'Università degli Studi della Campania Luigi Vanvitelli
Naples
Floriana.MORGILLO@unicampania.it
Floriana Morgillo
- Recruiting
I.F.O. Istituto Nazionale Tumori Regina Elena IRCCS
Rome
gabriele.minuti@gmail.com
Gabriele Minuti
- Recruiting
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
Torino
silvia.novello@unito.it
Silvia Novello
- Recruiting
Ospedale di Circolo
Varese
michele.flospergher@asst-settelaghi.it
Michele Flospergher
Spain9 sites, 6 recruiting
- Recruiting
Clinica Tres Torres
Barcelona
sviteri@oncorosell.com
Santiago Viteri Ramirez
- Terminated
Institut Universitari Dexeus-Quiron - Servei d oncologia medica - Institut Oncologic Dr. Rosell
Barcelona
- Terminated
Complejo Hospitalario Universitario Insular-Materno Infantil
Las Palmas de Gran Canaria
- Recruiting
Centro Integral Oncologico Clara Campa
Madrid
gmgarcialedo@hmhospitales.com
Gema Maria Garcia Ledo
- Terminated
Centro Oncologico MD Anderson
Madrid
- Recruiting
Hospital Regional Universitario de Malaga - Hospital General
Málaga
manuelcobodols@yahoo.es
Manuel Cobo Dols
- Recruiting
Hospidal Universitario Ntra. Sra. De Valme
Seville
fuentespradera@hotmail.com
Jose Fuentes Pradera
- Recruiting
Hospital Universitario Virgen Macarena
Seville
david.vbaz@gmail.com
David Vicente Baz
- Recruiting
Hospital Universitari i Politecnic La Fe de Valencia
Valencia
francisco_aparisi@iislafe.es
Francisco Aparisi
Israel8 sites, 8 recruiting
- Recruiting
Haemek Medical Center
Afula
gil_ba@clalit.org.il
Gil Bar-Sela
- Recruiting
Bnei-Zion Medical Center
Haifa
abed.agbarya@b-zion.org.il
Abed Agbarya
- Recruiting
Carmel Medical Center
Haifa
shulman_katherina@clalit.org.il
Katerina Shulman
- Recruiting
Rambam Medical Center - PPDS
Haifa
a_zerkuch@rambam.health.gov.il
Alona Zer Kuch
- Recruiting
Shaare Zedek Medical Center
Jerusalem
peled.nir@gmail.com
Nir Peled
- Recruiting
Rabin Medical Center Oncology Beilinson Campus
Petah Tikva
mormos1@clalit.org.il
Mor Moskovitz
- Recruiting
Chaim Sheba Medical Center
Ramat Gan
yair.bar@sheba.health.gov.il
Jair Bar
- Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv
sivansh@tlvmc.gov.il
Sivan Shamai
Netherlands5 sites, 5 recruiting
- Recruiting
VU Medisch Centrum
Amsterdam
s.hashemi@amsterdamumc.nl
Sayed Hashemi
- Recruiting
Universitair Medisch Centrum Groningen - Department of Medical Oncology
Groningen
a.j.van.der.wekken@umcg.nl
Anthonie van der Wekken
- Recruiting
Leiden University Medical Center
Leiden
e.f.smit@lumc.nl
Egbert Smit
- Recruiting
Z.O.L. Campus Sint Jan (975)
Roosendaal, 4708
maarten.criel@zol.be
Maarten Criel
- Recruiting
Erasmus MC
Rotterdam, South Holland, 3015 GD
m.paats@erasmusmc.nl
M.S. (Marthe) Paats
Belgium4 sites, 4 recruiting
- Recruiting
Jessa Ziekenhuis
Hasselt, 3500
kristof.cuppens@jessazh.be
Kristof Cuppens
- Recruiting
AZ Delta
Roeselare
ingel.demedts@azdelta.be
Ingel Demedts
- Recruiting
AZ Nikolaas
Sint-Niklaas
koen.deschepper@aznikolaas.be
Koen Deschepper
- Recruiting
Cliniques UCL de Mont-Godinne (7077)
Yvoir, 5530
sebahat.ocak@uclouvain.be
Sebahat Ocak
Canada4 sites, 4 recruiting
- Recruiting
Ottawa Hospital General Campus
Ottawa
pwheatleyprice@toh.ca
Paul Wheatley-Price
- Recruiting
Centre Intégré de Cancérologie du CHU de Québec
Québec, G1J0J9
nicolas.marcoux.1@ulaval.ca
Nicolas Macroux
- Recruiting
Princess Margaret Cancer Centre
Toronto
geoffrey.liu@uhn.ca
Geoffrey Liu
- Recruiting
British Columbia Cancer Agency (6864)
Vancouver, V5Z 4E6
cho@bccancer.bc.ca
Cheryl Ho
Germany4 sites, 4 recruiting
- Recruiting
Klinikum Chemnitz GmbH
Chemnitz
s.hammerschmidt@skc.de
Stefan Hammerschmidt
- Recruiting
KKH Grosshansdorf GmbH
Großhansdorf
m.reck@kh-grosshansdorf.de
Martin Reck
- Recruiting
Thoraxklinik-Heidelberg gGmbH
Heidelberg
michael.thomas@thoraxklinik-heidelberg.de
Michael Thomas
- Recruiting
Klinik Löwenstein GmbH
Löwenstein
onkologie@klinik-loewenstein.de
Jonas Kuon
Portugal4 sites, 4 recruiting
- Recruiting
Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
Lisbon
astl.machado@gmail.com
Andrea Machado
- Recruiting
ULS de Loures-Odivelas, EPE - Hospital de Loures
Loures, Lisbon District, 2674-514
carlota.vieira.baptista@ulslod.min-saude.pt
Carlota Baptista
- Recruiting
Centro Hospitalar do Porto E.P.E. Hospital de Santo António
Porto
antonio.araujo@chporto.min-saude.pt
Antonio Araujo
- Recruiting
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
Porto Covo
ana.fernandes.rodrigues@ipoporto.min-saude.pt
Ana Rodrigues
United States3 sites, 2 recruiting
- Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43221
david.carbone@osumc.edu
David Carbone
- Recruiting
Holy Cross Health
Fort Lauderdale, Florida, 33308-4603
guchuan@hotmail.com
David Drew
- Active, not recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
Austria3 sites, 3 recruiting
- Recruiting
Klinikum Klagenfurt Am Woerthersee
Klagenfurt
barbara.mittergradnegger@kabeg.at
Barbara Mittergradnegger
- Recruiting
Landeskrankenhaus Salzburg - Universitätsklinikum der PMU
Salzburg, 5020
m.studnicka@salk.at
Michael Studnicka
- Recruiting
Klinik Floridsdorf
Vienna
maximilian.hochmair@gesundheitsverbund.at
Maximilian Hochmair
Czechia2 sites, 2 recruiting
- Recruiting
FN Olomouc
Olomouc
bohuslav.melichar@fnol.cz
Bohuslav Melichar
- Recruiting
University Hospital Na Bulovce
Prague
petr.opalka@bulovka.cz
Petr Opalka
Sweden1 site, 1 recruiting
- Recruiting
Universitetssjukhuset i Linköping
Linköping
anders.vikstrom@regionostergotland.se
Anders Vikström
About this study
Official title: Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Read the detailed description
This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.
- Conditions
- Cancer
- Keywords
- Disease Registry, METex14 Skipping Alterations
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Advanced Non-small Cell Lung Cancer with METex14 skipping alterations | Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Best Overall Response (BOR)
Measured: Through study completion, up to approximately 4.9 years
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Measured: Up to approximately 4.9 years
Overall Survival (OS)
Measured: Through study completion, up to approximately 4.9 years
Number of Participants with Adverse Events (AEs)
Measured: Up to approximately 4.9 years
Number of Participants with Adverse Reactions (ARs)
Measured: Up to approximately 4.9 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 May 2022
- Study start4 Oct 2022
- Primary completion28 Apr 2028 (estimated)
- Study completion28 Apr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by EMD Serono Research & Development Institute, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 700 participants (estimated)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Merck KGaA, Darmstadt, Germany
- Responsible party
- Sponsor
- Investigators
- Medical Responsible, Study director, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05376891
- Sponsor's protocol ID
- MS200095_0050
- Status last verified
- Sep 2026
- First submitted
- 11 May 2022
- Last updated
- 2 Oct 2026
- Results posted
- No
- Individual data sharing
- No: IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
Publications
Thomas M, Christopoulos P, Iams WT, Mazieres J, Cortot AB, Peled N, Minuti G, Smit EF, Audhuy F, Berghoff K, Eggleton SP, Fries F, Hildenbrand M, Liu P, Mahmoudpour SH, Menzel C, Oksen D. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan 21.
PubMed 39836056
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
- ClinicalTrials.gov ID
- NCT05376891
- Acronym / sponsor ID
- MS200095_0050
- Conditions
- Cancer
- Keywords
- Disease Registry, METex14 Skipping Alterations
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Merck KGaA, Darmstadt, Germany
- Study start
- 4 Oct 2022 (actual)
- Primary completion
- 28 Apr 2028 (estimated)
- Study completion
- 28 Apr 2028 (estimated)
- First posted
- 17 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Detailed description
This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Advanced Non-small Cell Lung Cancer with METex14 skipping alterations | – | –Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Participants with advanced stage (stages IIIB-IV) NSCLC and confirmed METex14 skipping alterations who are initiating or already treated with a systemic therapy will be included.
Key inclusion criteria (3 listed)
- Participants who signed ICF
- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
- Participants who are starting or are already being treated with systemic therapy
Key exclusion criteria (1 listed)
- Participants who are enrolled in a clinical trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Best Overall Response (BOR)
Time frame: Through study completion, up to approximately 4.9 years
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Time frame: Up to approximately 4.9 years
Overall Survival (OS)
Time frame: Through study completion, up to approximately 4.9 years
Number of Participants with Adverse Events (AEs)
Time frame: Up to approximately 4.9 years
Number of Participants with Adverse Reactions (ARs)
Time frame: Up to approximately 4.9 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- Derived from this study: PubMed 39836056Thomas M, Christopoulos P, Iams WT, Mazieres J, Cortot AB, Peled N, Minuti G, Smit EF, Audhuy F, Berghoff K, Eggleton SP, Fries F, Hildenbrand M, Liu P, Mahmoudpour SH, Menzel C, Oksen D. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan 21.
- Trial Awareness and Transparency websiteLink provided by the sponsor.
- US Medical Information website, Medical ResourcesLink provided by the sponsor.
- Medical Information Location Map - Med Info ContactsLink provided by the sponsor.
- Individual participant dataSharing planned: No. IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
Related trials for Cancer
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Not yet recruitingPhase 2
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
Cachexia-Anorexia Syndrome, Cachexia; Cancer
RecruitingPhase 2
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Esophageal Squamous Cell Carcinoma, Immunotherapy
Not yet recruitingPhase 1/2
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Medical Responsible study director
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
80 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by EMD Serono Research & Development Institute, Inc. at 80 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 80 sites in United Kingdom, France, Italy, Spain, Israel and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact US Medical Information (888-275-7376, eMediUSA@emdserono.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Best Overall Response (BOR) (time frame: Through study completion, up to approximately 4.9 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05376891, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.